Comparing catecholamine levels in blood during adrenal artery embolization for hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between blood pressure fluctuations and catecholamine concentrations in patients with primary aldosteronism undergoing selective adrenal artery embolization (SAAE). The study aims to collect adrenal and peripheral venous blood samples during the procedure to analyze catecholamine levels and understand the mechanisms behind blood pressure changes. By identifying patterns in these fluctuations, the research seeks to provide insights that could improve the safety and efficacy of SAAE as a treatment for resistant hypertension. The findings may help clarify why some patients experience significant blood pressure increases during the procedure while others do not.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years with no gender restrictions.
2. Adherence to the "Primary Aldosteronism" Diagnosis and Treatment Guidelines, confirmed diagnosis of primary aldosteronism following rigorous drug washout, and identification as either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.
3. Blood pressure metrics that satisfy any of the subsequent conditions: a) Clinic-recorded blood pressure ≥140/90mmHg; b) 24-hour ambulatory blood pressure monitoring results displaying average blood pressure \>130/80 mmHg or daytime readings \>135/85 mmHg.
4. Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significant morphological deviations.
5. Hypertension history surpassing a duration of 6 months.
6. Prior to screening, patients or their lawful guardians must provide a signed informed consent, sanctioned by the ethics committee.

Exclusion Criteria:

1. Patients diagnosed with primary hypertension or secondary hypertension attributed to other etiologies.
2. Female participants who are presently pregnant, lactating, or with intentions to conceive within the forthcoming year.
3. Presence of significant systemic diseases, with particular attention to hepatic and renal dysfunction.
4. Pronounced allergic reaction to contrast agents.
5. Any other serious systemic diseases with a life expectancy of less than 12 months.
6. Participants concurrently enrolled or expressing interest to participate in other clinical trials, the outcomes of which could potentially influence the results of the current study.
7. The researcher's discretion deems the subject inappropriate for inclusion in the study for any given reason.

Where it's running

• The First Affiliated Hospital of Chengdu Medical College
  Chengdu, Sichuan, China Recruiting

Study contacts

• Principal investigator: Peijian Wang, PhD — First Affiliated Hospital of Chengdu Medical College
• Study coordinator: Peijian Wang, PhD
• Email: wpjmed@aliyun.com
• Phone: 028-83016145

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Gallium-68 Pentixafor PET-CT to improve surgery outcomes in primary aldosteronism

  This trial will test whether adding gallium-68 pentixafor PET/CT to standard adrenal venous sampling helps people with primary aldosteronism have better results from adrenal surgery.

  Recruiting at 2 sites Seoul National University Hospital · Seoul, Gangnam-gu and 1 other locations · NCT07027254

• Kidney stiffness measured by ultrasound in hypertension and healthy volunteers

  This study tests whether kidney stiffness measured by a non-invasive ultrasound method differs between people with high blood pressure and healthy individuals.

  Recruiting Azienda Ospedaliera di Padova · Padova, PD · NCT07914075

• Inclisiran vs. Statin for Primary Aldosteronism

  This trial tests whether inclisiran plus amlodipine works differently from a statin-based approach in people with primary aldosteronism and high blood pressure.

  Recruiting Third Military Medical University · Chongqing, Chongqing Municipality · NCT07884955

• Longer or shorter ablation duration in renal denervation to lower blood pressure

  In people with resistant hypertension, this study tests whether treating the main renal arteries for 2 minutes per site (vs 1 minute) leads to greater blood pressure reduction.

  Recruiting Ruijin Hospital · Shanghai · NCT07876479

• Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

  This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857044

• Metomidate PET-CT vs Usual Care for Primary Aldosteronism

  This study tests whether [11C] metomidate PET-CT can help orient treatment for people with primary aldosteronism compared with the usual adrenal venous sampling approach.

  Recruiting Chinese University of Hong Kong · Shatin · NCT07814105

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.